Reata Pharmaceuticals is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with life-threatening diseases, including chronic kidney disease. They are currently conducting clinical trials for bardoxolone methyl and omaveloxolone, as well as various forms of CKD. Reata Pharmaceuticals also has collaborations with Kyowa Kirin Co., Ltd. and AbbVie Inc. to develop and commercialize certain products across Asia.